High prevalence of anal high‐risk HPV infection among transwomen: estimates from a Brazilian RDS study.

Introduction: As the leading sexually transmitted infection worldwide, human papillomavirus (HPV) may disproportionately affect transwomen. We aimed to estimate anal HPV prevalence, especially focusing on high‐risk (hr)‐HPV types and evaluate their associated factors among transwomen living in Rio de Janeiro, Brazil. Methods: Transwomen enrolled in a respondent‐driven sampling (RDS)‐based survey conducted between August 2015 and January 2016 self‐collected anal samples, which were promptly stored at minus 80°C. After DNA extraction, HPV detection and genotyping were performed using the PapilloCheck test. We estimated HPV prevalences and evaluated the correlates of anal hr‐HPV infection using a regression logistic model. Results: Out of 345 transwomen, 272 (78.8%) were included in this analysis (122 [44.9%] HIV‐positive). No participant had ever received HPV vaccination. Among participants enrolled, 212 (77.9%) were positive for any anal HPV type and 165 (60.7%) for hr‐HPV. Most common hr‐HPV were as follows: HPV16 (17.6%), HPV68 (14.7%), HPV39 (14.3%), HPV56 (12.5%), HPV51 (11.4%) and HPV52 (11.0%). HIV‐positive transwomen had three times the odds of having an hr‐HPV compared to HIV‐negative transwomen. Participants who had a current rectal Neisseria gonorrhoeae infection had 3.7 times the odds of being coinfected with hr‐HPV. Among HIV‐positive transwomen, neither antiretroviral therapy use, undetectable viral load, current and nadir CD4 counts were associated with anal hr‐HPV infection. Conclusions: Brazilian transwomen in our study exhibit some of the highest population‐specific rates of HPV and hr‐HPV. There is an urgent need to elucidate the burden of HPV infection, prevalence of HPV‐related diseases and access to and uptake of HPV vaccination among transwomen, especially from low‐ and middle‐income settings. [ABSTRACT FROM AUTHOR]